Pierre Manzo, MD
Family Medicine · East Greenwich, RINPI 1033199468
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$835
- AbbVie$808
- AstraZeneca$803
- Pfizer$586
- Amgen$308
- GSK$293
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,357100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $835 |
| AbbVie(2 entities) | 45 | $808 |
| AstraZeneca | 44 | $803 |
| Pfizer | 37 | $586 |
| Amgen | 13 | $308 |
| GSK | 20 | $293 |
| Merck | 10 | $179 |
| Exact Sciences | 7 | $178 |
| Lilly USA, LLC | 8 | $131 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $124 |
| Antares Pharma, Inc. | 5 | $121 |
| Mayne Pharma Commercial LLC | 7 | $95 |
| E.r. Squibb & Sons, L.L.C. | 5 | $86 |
| Abbott | 4 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $82 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| Biohaven Pharmaceuticals, Inc. | 2 | $51 |
| Corium, LLC | 4 | $51 |
| Bayer | 2 | $48 |
| UCB, Inc. | 2 | $46 |
| Johnson & Johnson | 3 | $45 |
| Mylan Specialty L.p. | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $38 |
| Abiomed | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Coopersurgical, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Echosens North America, Inc. | 1 | $10 |
| Organon | 1 | $6 |
How this compares
$5,363 in reported general payments places this provider in the 90th percentile of 222 family medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $107,888 |
| EliquisApixaban | 36 | $39,163 |
| JardianceEmpagliflozin | 28 | $23,971 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,852 |
| FarxigaDapagliflozin Propanediol | 14 | $15,251 |
| MounjaroTirzepatide | 12 | $13,028 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $12,435 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $10,563 |
| Famotidine | 76 | $6,742 |
| MyrbetriqMirabegron | 14 | $6,662 |
| JanuviaSitagliptin Phosphate | 12 | $6,365 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $5,481 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $3,992 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,965 |
| Omeprazole | 233 | $3,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $835 | $107,88898 claims |
| PfizerEliquis | $586 | $39,16336 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $293 | $36,37976 claims |
| Boehringer IngelheimJardiance | $16 | $23,97128 claims |
| AstraZenecaFarxiga, Symbicort | $803 | $20,73337 claims |
| Lilly USA, LLCMounjaro | $131 | $13,02812 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $6,66214 claims |
| MerckJanuvia | $179 | $6,36512 claims |
| AbbVieSynthroid | $808 | $1,16634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 family medicine providers in Rhode Island.
Other family medicine in East Greenwich
- Ellen HightEast Greenwich$4K
- John SlatteryEast Greenwich$4K
- Lauren GoddardEast Greenwich$737
- Gina la ProvaCumberland$778K
- Wilfredo Giordano-PerezJohnston$351K
- Martin MinerProvidence$124K
- Frank la FaziaWest Warwick$19K
- Jamiel AmbradWakefield$18K
- Jason AustinJohnston$15K
- Mary SutterPawtucket$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.